



CONCORD DRUGS LIMITED

Admn. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R.Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Website : www.concorddrugs.in

To,

Date: 30.06.2020

BSE Limited,
P.J. Towers, Dalal Street,
Mumbai - 400001

Dear Sir/Madam,

Sub: Statement of Cash Flows for the year ended 31.03.2020

Ref: Our Company's letter dated 27.06.2020


In continuation of our letter dated 27.06.2020, please find enclosed the statement of cash flows for the year ended 31.03.2020

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Concord Drugs Limited

S. Koni Reddy



S. Koni Reddy
Whole-time Director & CFO
DIN: 02829319

Encl: as above

Statement of Cash flow for the year ended 31 March, 2020

Rs in Lakhs

Particulars	As at	
	March 31, 2020	March 31, 2019
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit before tax:	12.82	43.98
<i>Adjustments for:</i>		
Depreciation and amortisation expense	146.39	171.18
Finance costs	144.60	149.47
Interest income	(0.80)	(0.70)
Provision for Gratuity	-	-
Operating profit before working capital changes	303.01	363.92
<i>Changes in working capital:</i> (Refer Note 40)		
<i>Adjustments for (increase) / decrease in operating assets:</i>		
Financial Assets		
Trade receivables	2,298.87	2,273.76
Loans and Advances	(3.60)	-
Other Non Current assets	(0.03)	(0.78)
Inventories	221.03	(2.22)
Other Current assets	(117.22)	(39.07)
Other bank balances	-	-
Other Current financial Assets	-	8.58
<i>Adjustments for increase / (decrease) in operating liabilities:</i>		
Trade payables	(2,984.11)	(2,373.10)
Borrowings	-	(121.06)
Other current financial liabilities	-	(25.86)
Other current liabilities	0.19	44.07
Current tax liabilities, net	518.16	2.88
Provisions	-8.85	-
Deferred tax on amalgamation	-	-
Cash generated from operations	227.45	131.12
Net Income tax paid	(11.91)	(11.72)
Net cash flow from operating activities (A)	215.55	119.40
B. CASH FLOW FROM INVESTING ACTIVITIES		
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	(84.82)	(34.00)
Proceeds from maturity of fixed deposits	-	(1.10)
- Others	0.80	0.70
Net cash (used in) / flow from investing activities (B)	(84.02)	(34.39)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from issue of equity shares	88.20	-
Finance costs	(144.60)	(149.47)
Repayment of Borrowings	18.75	(271.88)
Repayment of short term Borrowings	(44.57)	13.16
Govt Grants	(8.61)	(7.61)
Other equity Adjustment	(55.37)	342.61
Net cash flow (used in) financing activities (C)	(146.21)	(73.19)
Net (decrease) in Cash and cash equivalents (A+B+C)	(14.68)	11.82
Cash and cash equivalents at the beginning of the year	15.89	4.08
Effect of exchange differences on translation of foreign currency Cash and cash equivalents	-	-
Cash and cash equivalents at the end of the year (Refer Note (i) below)	1.21	15.89
* Comprises:		
Balances with Banks	0.08	9.66
Others	1.13	6.23
	1.21	15.89

As per our report of even date

For and on behalf of the Board of Directors of
Concord Drugs Limited
CIN: L24230TG1995PLC020093

S. Nagi Reddy
(Nagi Reddy Seelam)
Managing Director
DIN: 01764665

S. Koni Reddy
(Koni Reddy Seelam)
Director*
DIN: 02829319



Place: Hyderabad
Date: 27-06-2020